Eli Lilly Signs $2.75 Billion Deal with Insilico for AI Drug Development
Eli Lilly, a leading American pharmaceutical company, has announced a strategic deal worth up to <strong>$2.75 billion</strong> with Hong Kong-based Insilico Medicine to develop drugs discovered using <strong>artificial intelligence</strong>. The agreement includes an initial payment of <strong>$115 million</strong>, with potential additional earnings tied to regulatory and commercial milestones.